PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 89628

Title: Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05270042

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Viet Nam

Author's Country/Territory: China

Manuscript submission date: 2023-11-07

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-11-28 10:28

Reviewer performed review: 2023-12-05 10:17

Review time: 6 Days and 23 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

1. The author should state more clearly the selection criteria, whether the patient was being treated with NAs, or had been treated and then stopped. If they stopped, how long had they stopped the treatments? 2. This is a medical research. To evaluate the results accurately, the author should use the same drug and the same manufacturing company. In this study, the author used many different types: Pegasys; Roche, Shanghai, China or Peginterferonα-2b; Amoytop Biotach, Xiamen, China. 3. Evaluation of treatment response should include additional factors such as normal ALT enzyme, negative HBVDNA. In addition, liver fibrosis should be assessed. 4.The author used many treatment regimens: PegINF mono, PegINF + ETV, PegINF + TDF. The author should discuss factors associated with the effectiveness of different regimens. 5. The 6-month follow-up period was a little short. The follow-up period should be longer, maybe 1 year because hepatitis B virus can recur slowly when treated with PegIFN.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 89628

Title: Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05270042

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Viet Nam

Author's Country/Territory: China

Manuscript submission date: 2023-11-07

Reviewer chosen by: Jing-Jie Wang

Reviewer accepted review: 2024-01-13 00:58

Reviewer performed review: 2024-01-13 01:19

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I accept author's answers.